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Abstract
Background: Subjective cognitive complaints are prevalent in those affected by functional psychoses and a variety of
possible associated factors have been investigated. However, few studies have examined these potential factors within
single studies or analyses.
Methods: Patients with a history of a schizophrenia spectrum disorder (n = 115) and a non-clinical comparison group
(n = 45) completed the Subjective Scale to Investigate Cognition in Schizophrenia (SSTICS) and the Brief Assessment of
Cognition in Schizophrenia (BACS). The patient group also completed the Positive and Negative Syndromes Scale (PANSS),
the Birchwood Insight Scale (IS), and the Hospital Anxiety and Depression Scale (HADS).
Results: The BACS and SSTICS scores were associated in the non-clinical comparison group, but not in the patient group. In
the patient group worse subjective cognition was associated positively with good insight, greater dysphoria and greater
positive symptoms. Linear regression revealed that, once other variables had been accounted for, dysphoria (HADS anxiety
and depression factor) was the only significant predictor of SSTICS scores.
Conclusions: Subjective cognitive impairment in patients with psychosis in the absence of formal testing should not be
taken as evidence of impaired cognitive functioning. Mood should be investigated when patients present with subjective
cognitive complaints.
Citation: Sellwood W, Morrison AP, Beck R, Heffernan S, Law H, et al. (2013) Subjective Cognitive Complaints in Schizophrenia: Relation to Antipsychotic
Medication Dose, Actual Cognitive Performance, Insight and Symptoms. PLoS ONE 8(12): e83774. doi:10.1371/journal.pone.0083774
Editor: Xiang Yang Zhang, Baylor College of Medicine, United States of America
Received January 14, 2013; Accepted November 12, 2013; Published December 20, 2013
Copyright:  2013 Sellwood et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This paper presents independent research commissioned by the National Institute for Health Research (NIHR), UK under its Programme Grants for
Applied Research scheme (RP-PG-0606-1086). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or
the Department of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sellwood@liverpool.ac.uk
Introduction
Self-report of cognitive deficits in schizophrenia is potentially
important. If patients can accurately report their own cognitive
problems this should help in the planning of interventions related
to functional outcome and individual therapy. In addition, it has
been suggested that for some, subjective cognitive complaints
(SCC) underlie a wide range of symptoms elicited from patients
that develop later as psychosis progresses and that there is
therefore an association between SCC and future psychotic
symptoms [1]. However, in a number of studies SCC and actual
cognitive performance is not associated and in those where there is
such an association, the relationship between these two variables is
weak[2,3,4,5]. Moreover, specific complaints are not mirrored on
relevant specific tests of neuropsychological function. This has
been explained in terms of the lack of ecological validity of
neuropsychological tests and patients misinterpreting terms such as
‘‘attention’’ and ‘‘memory’’. This raises the question as to what
SCC actually represents and what factors are involved in its
expression. A number of factors have been investigated in this
regard. Medication side effects [6,7,8], insight [4] and symptoms
associated with psychosis [9], including depression[2,10] have all
been found to be related to SCC. However, no studies have looked
at the relative predictive values of these variables, or whether they
contribute to predicting SCC independently or not. The aim of the
present study was to replicate the finding that patients’ subjective
experiences of cognitive functioning fail to reflect objectively
assessed cognitive performance[2,3,4,5] and to determine the
relative importance of possible predictors of subjective cognitive
complaints in schizophrenia. Specifically, once neuropsychological
performance and antipsychotic dose had been accounted for,
would SCC be predicted in terms of symptoms related directly to
psychosis, including insight? In addition, would anxiety and
depression predict SCC over and above psychotic symptoms?
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Methods
Ethical Statement
This study was conducted in accordance with guidelines set by
the UK NHS national ethics procedures (National Research
Ethics Service - NRES) and approved by the NHS trusts at local
levels (reference numbers 09/H1012/9 for clinical group and 10/
H1013/5 for comparison group). All participants (including those
aged 16 to 17 years) provided written informed consent and were
deemed to have capacity to provide informed consent by the
clinical team working with them. Recruitment and consent
procedures for all participants including those aged 16 to 17 years
were approved by the NRES committees.
Clinical participants
115 patients, 84 male and 31 female, mean age = 36.0 years
(SD=11.59), who had been diagnosed by their consultant
psychiatrists as suffering from a schizophrenia-spectrum disorder
according to ICD-10 criteria, aged 16–65, with a sufficient level of
English literacy to complete the measures and capacity to provide
informed consent, were referred from clinical teams in the North
West of England. The selection criteria were purposefully broad,
in order to recruit patients varying in their symptoms and duration
of illness. Although those with acquired brain injury or learning
disability were not excluded and presence of such a diagnosis
noted, none were recruited into the sample. The majority were
White British (83%). Twenty-six had no school qualifications, 35
had completed school level qualifications, 15 had experienced
higher education, and the rest had obtained vocational qualifica-
tions (data missing from 3). Four were in full or part-time
employment and 6 were students. Nine were in long-term
relationships and 10 were divorced or separated. Diagnoses,
confirmed using ICD-10 checklists, were as follows: schizophrenia
(n = 75), schizoaffective disorder (n = 10), unspecified non-organic
psychosis (n = 14), acute and transient psychotic disorder (n = 12),
and persistent delusional disorder (n = 4). Data on medication
were available for 93 patients; of these 11 were not taking
antipsychotics and 82 were (mean daily dose = 351.41 mg,
SD=221.04, CPZ equivalent calculated using the method of
[11] when possible, otherwise from the British National Formulary
(Joint Formulary Committee, 2007). Duration of illness was
estimated from participant’s reports of age of first psychotic
episode and was highly skewed (median= 140 months, range 8–
522; data missing from 5 participants). Data for this latter variable
were therefore log transformed for use in the analyses reported
below.
Comparison group
The comparison group comprised a convenience sample
recruited from local fire services; staff working in National Health
Services via posters displayed in office areas; and acquaintances of
the research assistants, using a snowballing method. The
comparison participants completed the study in the same way as
the patients, directly with the researcher, and were remunerated
for their time.
Thirty were male and 15 female, with a mean age of 34.6 years
(SD=11.72). Seventeen had obtained school-level qualifications,
17 had experienced higher education and the rest had vocational
qualifications. Fifteen were in long-term relationships and 2 were
separated.
Measures
Positive and Negative Syndromes Scale (PANSS). The
PANSS [12] is a clinician administered thirty-item semi-structured
interview consisting of seven items assessing positive symptoms
(Pos; e.g. hallucinations, delusions, conceptual disorganization),
seven items assessing negative symptoms (Neg; e.g. blunted affect,
passive/apathetic social avoidance) and sixteen items assessing
global psychopathology (e.g. depression, anxiety, lack of insight,
guilt). All items are scored between 1 (not present) and 7 (severe). A
number of studies have demonstrated the reliability and validity of
the PANSS. PANSS raters (RB, SH) were trained using a
standardised approach and had achieved good inter-rater reliabil-
ity (ICC=0.874, P,0.001).
Beck Hopelessness Scale. The Hopelessness Scale
(BHS[13]) was developed as a self-report measure regarding
pessimism about the future. There are 20 true/false items and
scores of 9 or above indicate a high risk of future suicide[14,15]. It
has a demonstrably high internal consistency and scores are
associated with levels of depression[13].
Hospital Anxiety and Depression Scale. The hospital
anxiety and depression scale (HADS; [16] is a 14 item self-report
measure. Of these items, 7 assess depression, whilst the remaining
7 assess anxiety over the preceding week. Cronbach’s alpha values
for anxiety and depression scales for this sample are a=0.86 and
a=0.83 respectively. Because these scales were highly correlated
(r = .67, p,000) scores were added to derive a single dysphoria
score for subsequent analyses (alpha = .90) (Using separate anxiety
and depression scores did not appreciably alter any of the results).
Birchwood Insight Scale. Insight was measured with the
Insight Scale (IS; [17], an 8-item self-report scale designed to be
sensitive to change, and which captures three widely accepted
dimensions of insight: perceived need for treatment, awareness of
illness and relabeling of symptoms as pathological. Higher scores
indicate greater levels of insight. In this study the scale had an
alpha coefficient of 0.66.
Brief Assessment of Cognition in Schizophrenia (BACS)
The Brief Assessment of Cognition in Schizophrenia (BACS;
[18,19] is a battery of neurocognitive tests that assesses domains of
cognition found to be most impaired and most strongly correlated
with outcome in patients with a diagnosis of schizophrenia. These
include verbal memory, working memory, motor speed, verbal
fluency, attention and speed of processing and executive function.
The BACS has 6 subscales (list learning, digit sequencing task,
token motor task, verbal fluency, Tower problem solving, and
symbol coding), takes approximately 35 minutes to complete and
has high levels of test re-test reliability on each of the subscales and
with parallel forms for those subtests where they were available. In
this study, the token motor task (in which participants are asked to
pick up small tokens in both hands simultaneously and place them
in a basket) was omitted after it was found to be poorly tolerated.
Therefore rather than use the total BACS score the data were
factor analysed and the single resultant factor used in susequent
analyses. The BACS has an equivalent sensitivity to the detection
of impairments as a standard, more extensive, neuropsychological
test battery [19].
Subjective Scale to Investigate Cognition in
Schizophrenia (SSTICS)
The SSTICS [20] is a brief, 21 item self report scale examining
subjective complaints about memory, attention, praxia and
executive function in patients affected by schizophrenia. In the
original study it exhibited good internal consistency (a= .86) and
test-retest reliability (rs = .82). In this study, the internal consistency
(a) was.90 across the two groups. Specific areas of cognition
covered are working memory, explicit memory (divided into
episodic and semantic memory), attention, executive function and
Subjective Cognitive Complaints in Schizophrenia
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language. There are five subscales: explicit memory, episodic
memory, semantic memory, working memory and attention. Stip
et al. reported significant but weak associations between the
memory subscales and objectively assessed mnemonic function.
The 21 items take approximately six minutes to complete.
Results
Comparison of groups
Table 1 shows mean scores of the two groups on measures of
mood, subjective and objective cognition. Significant differences
were observed between the groups on all of the variables with the
exception of the SSTICS working memory subscale. Pearson
correlation coefficients revealed a modest and marginally signif-
icant correlation between total BACS and total SSTICS scores for
the non-clinical comparison group (r =2.31, p = .05, n= 41) but
no correlation for the patients (r =2.05, p = .62, n= 117).
Although these correlations differed in terms of significance level,
they did not differ significantly from each other (z = 1.44, ns).
It might be argued that insight should moderate the relationship
between BACS and SSTICS, so that only patients with good
insight will correctly judge their cognitive ability. To test for this
possibility, a multiple regression was carried out using centred
variables, with SSTICS total scores as the dependent variable,
total insight and total BACS scores entered as predictors in the first
stage, and then the interaction between the BACS and insight
scores entered in the second stage. When the BACS and insight
variables were entered, there was a significant model
(F[2,103] = 4.113, p,.02, adjusted r
2 = .056) but only insight was
retained as a significant predictor (b= .27, t = 2.86, p,.005).
However, adding the interaction between insight and BACS scores
in the second stage did not improve the model (Fchange = .55,
p = .46) and the effect of the interaction was nonsignificant.
Predictors of subjective cognitive impairment in the
patient group
Correlations between SSTICS and BACS subscales for the
patient group are shown in Table 2 with those for the non-clinical
comparison group summarized in Table 3. It can be seen that
none of the SSTICS subscales were associated significantly with
any of the BACS subscales in the clinical group. In addition the
SSTICS total scores and single factor scores on the BACS (see
below) were not associated (Pearson’s r = .006; ns). One possibility
was that level of education may have not only been related to
BACS scores, but also the reporting of SCC. Table 4 provides a
summary of correlations between the SSTICS, BACS factor scores
and symptom variables. It can be seen that positive symptoms,
insight and dysphoria exhibited significant correlations with the
SSTICS such that better insight, worse positive symptoms and
greater dysphoria were associated with poorer subjective cognitive
functioning. It is noteworthy that dysphoria was associated
significantly with insight and positive symptoms. Using the highly
conservative Bonferroni method of correcting for multiple
comparisons between the four clinical scales (PANSS positive,
PANSS negative, dysphoria and insight) and the two cognitive
measures (BACS and SSTICS) does not alter the overall picture
(critical p= .00625).
Spearman correlations revealed that whilst the BACS factor was
associated significantly with educational attainment (r = .37,
p,.01) the SSTICS total scores were not (r = .03, ns). A further
possible confound is that of diagnosis. Given the inclusion of
participants with schizoaffective disorder and other psychoses the
bivariate correlations between dysphoria and SSTICS total score
was re-run with only those with a primary diagnosis of
schizophrenia. The correlation remained significant (r = 0.66,
p,.000, n = 72).
Linear regression was used to assess the relative value of relevant
variables in predicting subjective cognition (SSTICS total scores).
13 participants were excluded from the analyses because of
missing data on one or more scale. For the purpose of analysis,
principle components analysis was used to derive a single factor
score for the BACS (Eigenvalue = 2.991, % variance accounted
for = 49.84, minimum loading = .58). Variables were entered in
three stages: first BACS scores, second clinical variables (PANSS
positive and negative and Birchwood Insight scores), and finally
mood measures (HADS dysphoria and the Beck Hopelessness
Scale scores). At each stage, the variables were entered simulta-
neously. Finally, the analyses were repeated with medication dose
and duration of illness (log transformed) included at the first stage
(this further reduced the sample size to 82 because data were
missing for these variables for some of the participants.)
It can be seen from Table 5 that BACS scores did not
significantly predict subjective cognitive functioning (p for initial
model = .90). At the second stage, a significant model was
generated (F[4,97] = 5.04, p,.001; adjusted R2= .14) and greater
insight and positive symptoms of psychosis predicted SSTICS
scores. Adding the dysphoria variables improved the model (final
F[6,95] = 10.78; adjusted R2= .37, p,.001). At this stage,
dysphoria was a significant predictor but the findings also
suggested that negative symptoms were weakly although negatively
associated with subjective cognitive function (less severe negative
symptoms were associated with poorer subjective cognitive
functioning).
When the analyses were repeated with duration of illness and
antipsychotic medication dose included, the results were essentially
unchanged except that the effect for negative symptoms was
removed (final F[8,73] = 7.27, p,.001; adjusted R2= .38) and
dysphoria remained the only significant predictor (see Table 6).
Table 1. Between group differences in depression, anxiety,
objective cognition and subjective cognition.
Patients Controls
Mean SD N Mean SD N p
HADS Depression 6.11 4.37 110 2.69 2.82 42 ,0.001
HADS Anxiety 8.78 4.98 110 4.98 3.32 42 ,0.001
BACS
Verbal memory 30.77 11.18 112 48.80 8.64 45 ,0.001
Letter fluency 20.99 7.89 112 31.04 9.42 45 ,0.001
Digit sequencing 15.89 3.97 112 20.96 3.72 45 ,0.001
Semantic fluency 19.64 6.38 112 27.04 5.66 45 ,0.001
Symbol coding 39.23 13.55 111 60.98 11.01 44 ,0.001
Tower of London 30.49 8.10 111 35.91 4.11 44 ,0.001
SSTICS
Memory total 16.77 7.47 112 13.29 7.46 42 0.011
Explicit memory 12.02 6.00 112 8.83 5.93 42 0.004
Episodic memory 8.96 4.66 112 6.83 4.94 42 0.014
Semantic memory 3.05 2.17 112 2.00 1.65 43 0.005
Working memory 4.75 2.04 112 4.51 1.94 43 ns
Attention 8.84 4.44 112 5.67 4.02 43 ,0.001
doi:10.1371/journal.pone.0083774.t001
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Discussion
Summary of results and implications
The aim of the present study was to determine the relative
importance of possible predictors of subjective cognitive com-
plaints in schizophrenia and to replicate the finding that patients’
subjective experiences of cognitive functioning fail to reflect
objectively assessed cognitive performance[2,3,4,5]. As in previous
studies, SCC was not associated with cognitive test performance in
patients with psychosis. However, in the non-clinical comparison
group there was an association between cognitive function and
SCC, indicating that healthy individuals are able to more
accurately appraise their own mental functioning than patients.
However, this association was relatively weak and the correlations
between SCC and performance on the BACS in the clinical and
non-clinical groups were not significantly different.
Some studies have shown that the association between cognitive
performance and negative symptoms is mediated by defeatist
beliefs [21,22]. However, SCC as measured in the present study
are unlikely to play this mediational role, as they failed to correlate
with either negative symptoms or actual cognition. One possible
explanation is that defeatist beliefs arise when cognitive failures
that the patient is unaware of impair social functioning. However,
it should be noted that in the first regression analysis (Table 5) it
can be seen that negative symptoms are inversely related to SCC.
In the final analysis this relationship disappeared once antipsy-
chotic dose and duration of illness had been accounted for.
The present findings call in to question the use of the SSTICS as
a means of evaluating cognition in those affected by psychosis. It
has been argued that some everyday cognitive failures that are
recognised by patients may be too subtle to be detected by
neurocognitive tests [23]. However, other factors, included in the
present study, appear to be important in determining patients’
beliefs about their own cognitive functioning.
Consistent with a previous study of multiple factors [24], insight,
anxiety and depression and positive symptoms were associated
with subjective cognition. In the latter report the focus was on the
role of insight; anxiety and depression were entered as covariates,
leading to the relationship between insight and SCC being non-
significant, but the authors did not highlight the implications of
this finding. In fact, in the present study, anxiety and depression
derived from the HADS were the only clear predictors of SCC
once levels of medication, positive symptoms and negative
symptoms had been accounted for. It is therefore likely that
dysphoric symptoms account for patients’ reports of cognitive
problems.
It has been suggested that self-reports are affected in two ways.
First, those affected by cognitive deficits may lack cognitive
abilities to recognize deficits, whilst those whose abilities are
unimpaired overestimate the scale of their problems. One possible
explanation for the association between dysphoria and SCC is that
people affected by anxiety and depression may be more likely to
attribute their difficulties to poor memory or cognitive problems.
This would be consistent with a substantial research literature that
shows that depression is associated with a tendency to attribute
negative experiences to internal causes [25]. Patients with
depression may be excessively sensitive to normally occurring
cognitive failures, taking the view that their ‘brain is broken’,
Table 2. Correlations between STICSS and BACS subscale scores in the patient group.
SSTICS sub-scale
Digit sequencing
Total Semantic Fluency Symbol Coding Verbal Memory Letter Fluency Tower of London
Memory Total Pearson’s r 2.107 2.015 .099 2.094 2.010 .147
p .263 .879 .300 .325 .917 .124
n 112 112 111 112 112 111
Explicit Memory Pearson’s r 2.128 2.013 .070 2.091 2.023 .149
p .179 .894 .463 .338 .813 .118
n 112 112 111 112 112 111
Episodic Memory Pearson’s r 2.124 2.053 .022 2.099 2.060 .126
p .193 .582 .817 .301 .527 .187
n 112 112 111 112 112 111
Semantic Memory Pearson’s r 2.088 .077 .146 2.041 .067 .146
p .356 .417 .125 .668 .484 .127
n 112 112 111 112 112 111
Working Memory Pearson’s r 2.014 2.016 .157 2.075 .030 .098
p .880 .868 .099 .430 .753 .308
n 112 112 111 112 112 111
Attention Total Pearson’s r .043 2.043 .124 .067 .063 .136
p .653 .652 .193 .481 .510 .153
n 112 112 111 112 112 111
Executive Function Pearson’s r .043 .012 2.112 .002 .004 .075
p .653 .903 .241 .985 .964 .431
n 112 112 111 112 112 111
**Correlation is significant at the 0.01 level (2-tailed).
*Correlation is significant at the 0.05 level (2-tailed).
doi:10.1371/journal.pone.0083774.t002
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especially if this message has been passed on to them by clinicians.
It has been found that those experiencing psychosis, as well as
those at risk of psychotic symptoms, exhibit less confidence in their
cognitive abilities and are more self-conscious about them
compared to controls [26]. These factors are a key aspect of
certain anxiety disorders and depression where low ‘cognitive
confidence’ plays a role in maintaining problems [27,28].
In addition to the emotional aspects of SCC a further issue for
investigation may be metacognition; that is the ability to recognize
and manage one’s own cognitive functioning. In this sense it
should be related to insight. The present study suggests however,
that insight has less predictive value for SCC once dysphoria is
included in the equation. The same though may not be the case
for broader areas of function. It is recognized for example that
many patients under report problems with independent ‘real
world’ functioning [29], but this is unlikely to be the result of
depression or anxiety but is associated with insight[30]. In fact,
depression and anxiety may result from realization of difficulties
associated with psychosis [31] and are thus possibly inversely
related to impairment of insight.
Methodological limitations
There were certain limitations in the present study that should
be considered. First, the non-clinical comparison group was not
precisely matched to the patient group, especially in educational
attainment. It was also was small (n = 45) compared with the
clinical group. In addition there were some missing data,
particularly concerning medication. This latter point is potentially
important, because further questions may be raised about the roles
of different categories of antipsychotic (e.g. first versus second
generation treatments) as well as treatments for side effects.
Although the HADs is a widely used scale for determining levels
of anxiety and depression, its use with participant groups affected
by psychosis could be questioned. In relation to depression, scales
have been developed focusing on signs and symptoms which are
unlikely to be confused with antipsychotic medication side effects
and negative symptoms[32,33,34]. This might have given a more
rigorous specification of depression over and above these
confounding aspects of psychotic disorders. The choice of the
HADS was based upon the practical constraints of having to assess
many patients and burdening them with a minimal interview
length. It should be noted that one of the BACS subtests was
dropped because of some participants’ limited willingness to
tolerate the testing. Future work I this area should try to better
disentangle depression and anxiety from the effects of the
psychotic disorders of concern and the side effects of their
treatment.
A further potential measurement issue relates to the breadth
and refinement of other symptom clusters. For example, one
possibility in future work might be the evaluation of the role of
other symptom factors derived from the PANSS[35]. For example
what might be the role of the excitement and in particular
cognitive/disorganized factors? This question could be answered
by studies with larger participant samples with suitable levels of
power allowing for the inclusion of more variables in regression
analyses.
Table 3. Correlations between STICSS and BACS subscale scores in the non-patient group.
SSTICS sub-scale
Digit sequencing
Total Semantic Fluency Symbol Coding Verbal Memory Letter Fluency Tower of London
Memory Total Pearson’s r 2.278 2.142 2.172 2.307* 2.211 2.275
p .074 .370 .281 .048 .181 .078
n 42 42 41 42 42 42
Explicit Memory Pearson’s r 2.225 2.134 2.143 2.318* 2.201 2.267
p .153 .397 .372 .040 .201 .088
n 42 42 41 42 42 42
Episodic Memory Pearson’s r 2.209 2.165 2.118 2.304* 2.170 2.272
p .184 .297 .464 .050 .281 .082
n 42 42 41 42 42 42
Semantic Memory Pearson’s r 2.177 .010 2.160 2.228 2.210 2.143
p .257 .948 .313 .142 .177 .362
n 43 43 42 43 43 43
Working Memory Pearson’s r 2.340* 2.189 2.234 2.227 2.214 2.224
p .026 .225 .135 .143 .168 .149
n 43 43 42 43 43 43
Attention Total Pearson’s r 2.089 2.274 2.042 2.271 2.247 2.335*
p .570 .075 .789 .079 .110 .028
n 43 43 42 43 43 43
Executive Function Pearson’s r 2.081 2.311* 2.067 2.238 2.030 2.068
p .606 .042 .674 .124 .846 .665
n 43 43 42 43 43 43
**Correlation is significant at the 0.01 level (2-tailed).
*Correlation is significant at the 0.05 level (2-tailed).
doi:10.1371/journal.pone.0083774.t003
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Implications and future research
The major clinical implication is that clinicians should
investigate and consider the role of depression and anxiety when
confronted with patients with marked SCC. SCC in the absence of
formal cognitive testing should not be considered evidence of
impaired cognitive functioning. In addition, others have pointed
out that reports from other informants can improve the accuracy
of such judgments and where possible should be incorporated into
interviews regarding cognitive performance [36,37]. This is also
the case in trials where interview based assessments of cognition
are used as outcome variables [38].
Further more sophisticated methods might be used to examine
the role of relevant variables in predicting SCC. For example Kim
and Byun [6] found that, when medication doses were equated
and patients divided by level of side effects, those reporting most
side effects also reported higher levels of SCC. Thus there may be
variables not associated with dysphoric symptoms or at least only
partially so, that may explain SCC further, and which need to be
considered in future studies. It would also be useful to investigate
SCC longitudinally to determine, for example, whether they
change over time with changing mood, and also whether they are
more prominent at some stages of psychosis (e.g. acute episodes)
than at others (e.g. during the prodromal period or in remission).
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Dysphoria (HADS) 1.002 .205 .630***





Table 6. Multiple regression analysis 2 (inclusion of duration
of psychosis and medication level).
Step B Std. Error b
1 Constant 27.448 7.805
BACS Factor score .409 1.550 .030
Duration of Psychosis 1.338 1.764 .095
CPZ daily equivalents 2.007 .007 2.127
2 Constant 8.857 9.735
BACS Factor score 1.144 1.654 .084
Duration of Psychosis .054 1.678 .004
CPZ daily equivalents 2.010 .007 2.178
PANSS Positive Total .710 .268 .310**
PANSS Negative Total .118 .362 .042
Insight 1.258 .479 .284**
3 Constant 11.796 8.323
BACS Factor score 2.192 1.421 2.014
Duration of Psychosis 1.025 1.434 .073
CPZ daily equivalents 2.009 .006 2.154
PANSS Positive Total 2.018 .261 2.008
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Insight .599 .424 .135
Hopelessness 2.211 .299 2.092
Dysphoria (HADS) .988 .206 .680***
R2 step 1 =2.02; DR2 step 2 = .18; DR2 step 3 = .24.
*P = 0.01; ***p,0.001.
doi:10.1371/journal.pone.0083774.t006
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